comparemela.com

Latest Breaking News On - டெல்பி ஜெநெடிக்ஸ் - Page 1 : comparemela.com

Clone Competent Cell Market Innovative Growth Strategy by 2028 – Merck KGaA,Thermo Fisher Scientific,Agilent Technologies – KSU

Catalent acquires facility in Belgium for commercial-scale plasmid DNA manufacturing

Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary

Catalent Acquires Additional Facility at its Gosselies, Belgium Campus for Commercial-Scale Plasmid DNA Manufacturing

Catalent Acquires Additional Facility at its Gosselies, Belgium Campus for Commercial-Scale Plasmid DNA Manufacturing Share Article Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Promethera Biosciences, the world leader in advanced therapy development for severe liver diseases, today announced that Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its 32,400 square-foot (3,010 square-meter) facility in Gosselies, Belgium. The facility will accommodate Catalent’s new commercial-scale plasmid DNA (pDNA) manufacturing and will provide the opportunity for the immediate growth of Catalent’s pDNA service offering, which was recently acquired from Delphi Genetics to support the growing cell and gene therapy pipeline.

Catalent (NYSE:CTLT) - Catalent Buys Promethera s Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts

Catalent (NYSE:CTLT) - Catalent Buys Promethera s Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Catalent Inc (CTLT) Q3 2021 Earnings Call Transcript

Catalent Inc (CTLT) Q3 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Catalent Inc (NYSE: CTLT) Operator Good day and thank you for standing by. Welcome to the Catalent Third Quarter Fiscal Year 2021 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers presentation, there will be a question and answer session. [Operator Instructions] I would now like to hand the conference over to your speaker today, Paul Surdez, of Investor Relations.SPONSORED: 10 stocks we like better than Catalent When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.